A Trial of Low-dose Adjunctive alTeplase During prIMary PCI
Status:
Completed
Trial end date:
2019-05-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of reduced doses (10 mg and
20 mg) of intra-coronary alteplase compared with placebo as an adjunct to PCI in reducing MVO
and its consequences in high risk patients with STEMI.
Phase:
Phase 2
Details
Lead Sponsor:
NHS Greater Glasgow and Clyde
Collaborators:
National Institute for Health Research, United Kingdom University of Glasgow